Leucovorin + 5-fluorouracil plus dipyridamole in leucovorin + 5-fluorouracil-pretreated patients with advanced colorectal cancer: a pilot study of three different dipyridamole regimens.

作者: Nicolas Tsavaris , Christos Kosmas , Aristidis Polyzos , Kostadinos Genatas , Maria Vadiaka

DOI: 10.1177/030089160108700505

关键词:

摘要: Dipyridamole, an inhibitor of nucleoside transport, increases the activity 5-fluorouracil in a dose-dependent manner. The purpose present study was to determine whether dipyridamole with and leucovorin gave improved therapeutic outcome. Sixty patients entered pilot had previously received (450 mg/m2) (100 mg/m2), every week, relapsed during this treatment, which ended at least 6 weeks prior entry. Dipyridamole administered three different dosing schedules (DS) methods administration groups patients. DS I: dipyridamole, 30 mg/m2 normal saline solution, 90 min iv infusion, followed by leucovorin, 100 push, 5-fluorouracil, 450 60 tablets (75 mg) 12 hrs, continuously time chemotherapy. II: 50 rest same as I. III: without oral (50 manner I II. Treatment continued until tumor progression or unacceptable toxicity. All (n = 60) were assessable for response No complete observed. patient responded, whereas 2 II 3 III partial (P <0.1). Stable disease found 1), 8) 9) <0.01). More progressed 19) than 10) <0.0007). median duration 11 (range, 8-16). Time 17 I, 15 10-19) II, 14 11-21) 0.43). Median survival did not differ significantly between (29 weeks; range, 14-48), II(31.5 17-63) (36 16-58) 0.2). Neutropenia most severe (grade 2, P<0.01) 1, P<0.05) nausea/vomiting 0, P < 0.0005, grade <0.0002, <0.02) 3, P<0.0009). Diarrhea <0.005). Mucositis increased <0.008), anorexia <0.032) fatigue <0.003). other two experienced headache <0.044). According achieved (15% 45% stable disease) toxicity well tolerated mainly (except nausea vomiting <0.009), it can be stated that is appropriate dose simplest schedule (administration therapy only). In conclusion, appears might still have role enhancing clinical drugs involved inhibition thymidylate synthetase biochemical pathway its combination these agents (5-fluorouracil + leucovorin) frontline treatment should therefore explored future phase studies.

参考文章(30)
ARP Paterson, ES Jakobs, CYC Ng, RD Odegard, AA Adjei, None, Nucleoside Transport Inhibition In Vitro and In Vivo Topics and Perspectives in Adenosine Research. pp. 89- 101 ,(1987) , 10.1007/978-3-642-45619-0_8
D. Adelstein, J. Weick, R. Bukowski, D. Grabowski, G. T. Budd, S. Murthy, L. Bauer, A. Jayaraj, J. Boyett, Phase I Trial of Dipyridamole with 5-Fluorouracil and Folinic Acid Cancer Research. ,vol. 50, pp. 7206- 7211 ,(1990)
Concepcion Risueno, Kendra Tutsch, James K. V. Willson, Joan Bruggink, Paul H. Fischer, Alan Ranhosky, Donald L. Trump, Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion. Cancer Research. ,vol. 48, pp. 5591- 5596 ,(1988)
Stephen Cleary, Thomas C. K. Chan, Stephen B. Howell, Maurie Markman, Plasma Uridine Changes in Cancer Patients Treated with the Combination of Dipyridamole and N-Phosphonacetyl-l-aspartate Cancer Research. ,vol. 46, pp. 3168- 3172 ,(1986)
Scot C. Remick, Kendra D. Tutsch, Jean L. Grem, Lavonne M. Nieting, Dona B. Alberti, James K V Willson, James K V Willson, James K V Willson, Joan Bruggink, Paul H. Fischer, Mary B. Tombes, Donald L. Trump, Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. Cancer Research. ,vol. 50, pp. 2667- 2672 ,(1990)
C H Köhne, W Hiddemann, J Schüller, J Weiss, H P Lohrmann, U Schmitz-Hübner, H Bodenstein, C Schöber, H Wilke, J Grem, Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. Journal of Clinical Oncology. ,vol. 13, pp. 1201- 1208 ,(1995) , 10.1200/JCO.1995.13.5.1201
Maurie Markman, Thomas C. K. Chan, Stephen Cleary, Stephen B. Howell, Phase I trial of combination therapy of cancer with N -phosphanacetyl-L-aspartic acid and dipyridamole Cancer Chemotherapy and Pharmacology. ,vol. 19, pp. 80- 83 ,(1987) , 10.1007/BF00296262
P G Smith, E Marshman, D R Newell, N J Curtin, Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport British Journal of Cancer. ,vol. 82, pp. 924- 930 ,(2000) , 10.1054/BJOC.1999.1020
J.L. Grem, P.H. Fischer, Enhancement of 5-fluorouracil's anticancer activity by dipyridamole Pharmacology & Therapeutics. ,vol. 40, pp. 349- 371 ,(1989) , 10.1016/0163-7258(89)90084-3